Výsledky vyhledávání - "Doug Buckley"

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

Autor: Marie O’Farrell, Doug Buckley, George Kemble

Publikováno v: Journal of Hepatology. 73:S671

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5416455d99e0acdfb00f4f713683de7d
https://doi.org/10.1016/s0168-8278(20)31803-1

Zobrazit plný text záznamu

Abstract LB-214: FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study

Autor: Joanna Waszczuk, Marina Fridlib, Doug Buckley, William McCulloch, Richard Crowley, Marie O'Farrell, Claudia Rubio, Katharine Grimmer, Julie Lai, George Kemble, Richard Benn Abegania Ventura, Tim Heuer

Publikováno v: Cancer Research. 76:LB-214

TVB-2640 is an oral, first-in-class, selective and reversible inhibitor of fatty acid synthase (FASN) in Phase 1 testing in solid tumor patients (study 3V2640-CLIN-002). FASN is a central mediator of neoplastic lipogenesis and uniquely catalyzes the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f83057e6e32f27edd75210ae9e587ca2
https://doi.org/10.1158/1538-7445.am2016-lb-214

Zobrazit plný text záznamu

[Untitled]

Autor: Doug Buckley, Ron Mischak, Y. J. Wang, Gert Eberlein, Dana W. Aswad, Zahra Shahrokh, Mallik V. Paranandi, Pamela Stratton

Publikováno v: Pharmaceutical Research. 11:936-944

The degradation products of basic fibroblast growth factor (bFGF) were isolated by ion exchange HPLC (HP-IEC) and characterized. The predominant product at pH 5 was a succinimide in place of aspartate15 as determined by LC/MS, N-terminal sequencing,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0343f94c66d32e566f2cfe585a5b9b6
https://doi.org/10.1023/a:1018962732067

Zobrazit plný text záznamu

Abstract A75: Translational studies of a first-in-class FASN Inhibitor, TVB-2640, linking preclinical studies to clinical laboratory observations in solid tumor patients

Autor: George Kemble, Doug Buckley, Marie O'Farrell, Bill McCulloch, Tim Heuer

Publikováno v: Molecular Cancer Research. 14:A75-A75

Dysregulated expression of FASN is a central mediator of neoplastic lipogenesis. FASN catalyzes the production of palmitate, the building block of long chain fatty acids, providing a mechanism to convert glucose and other carbon sources into lipids n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e24498a3bd4ff51b940871f92e61113c
https://doi.org/10.1158/1557-3125.metca15-a75

Zobrazit plný text záznamu

Abstract 2675: Biomarker and PK/PD analyses of first in class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients

Autor: Timothy S. Heuer, Richard Crowley, C. Rubino, Marie O'Farrell, Doug Buckley, William McCulloch, George Kemble

Publikováno v: Cancer Research. 75:2675-2675

TVB-2640 is a potent, reversible and selective fatty acid synthase (FASN) inhibitor currently in its first Phase 1 study (3V2640-CLIN-002) in solid tumor patients. This study includes biomarker assays for this first in class agent to assess pharmacod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bf2a4f26b473cbba50d388e67e1a6ff
https://doi.org/10.1158/1538-7445.am2015-2675

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání